Overview

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

Status:
Completed
Trial end date:
2017-05-17
Target enrollment:
Participant gender:
Summary
This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals